Surgical Innovations Group (LSE:SUN) has entered a new chapter under a new chief executive. Alex Warnock took over as chief executive on 1 October 2026, replacing David Marsh, who has become a non-executive director. The change, announced on 28 September, came just before the medical device company published half-year results on 30 September showing broadly flat Revenue and a small pre-tax loss.

What the Company Does

Surgical Innovations designs, manufactures and distributes devices for minimally invasive surgery, including port access systems, surgical instruments and retraction devices. Many of its products use what it calls a "Resposable" concept, combining reusable and single-use components, and its Logi range is being extended. The group also makes devices for original equipment manufacturer partners, and its Subsidiary Elemental Healthcare distributes specialist third-party products in the UK. The company refers to its Manufacturing as UK-based.

Latest Developments

According to the board change announcement, Mr Warnock has more than 25 years of senior operational experience in high-tech manufacturing, photonics and regulated medical technology, including a period as group managing director of SDI Group. Mr Marsh, who co-founded Elemental Healthcare, will continue to support the business, including on key relationships. In July 2026, Elemental secured a place on the NHS Minimally Invasive Surgery 3 framework for an initial two years from 10 August 2026. The company said more than 60% of Elemental's sales currently flow through this framework, while noting that inclusion does not guarantee sales.

Financial Picture

For the six months to 30 June 2026, revenue was £6.02 million, compared with £6.15 million a year earlier. Gross Margin fell to 29.0% from 31.2%, adjusted EBITDA was about £0.03 million, down from £0.37 million, and the group recorded a loss before tax of about £0.25 million against a small profit in the prior period. Sales of own-branded products declined to £3.08 million, while OEM revenue rose 5% to £1.00 million and UK distribution revenue increased. By region, the UK edged higher, Asia-Pacific grew 29% helped by Japan, and Europe and the US declined, with the company citing a distributor transition in Europe and tariffs in the US. Cash was £0.36 million at 30 June, with net Debt of £0.3 million after invoice financing, and the remaining Covid-era CBILS Loan was repaid in May. For the full year 2025, revenue was £11.6 million and the loss after tax was about £0.9 million. The interim report did not mention a dividend.

Sector and index Context

The company is one of the smaller healthcare names in the FTSE AIM All Share Index. Medical device makers of its size face strict regulatory requirements and pricing pressure from large health systems, and Surgical Innovations relies heavily on NHS purchasing in the UK. The company said it has achieved certification under the EU Medical Device Regulation and completed UKCA and MDSAP audits.

Key Risks

Margins have been under pressure, and the Balance Sheet offers limited headroom, with invoice financing headroom of about £0.2 million at the half-year. US tariffs are expected to continue weighing on sales in the near term, and a Supply constraint on one key OEM component was noted. Leadership change also brings execution risk as the new chief executive settles in.

What to Watch Next

The company has said it expects a return to growth in the UK and Europe in the second half of 2026, supported by several price increases. New products, including Logitube Lux and the YelloPort Balloon Port, are planned for the fourth quarter. Investors will also look for any strategic update from Mr Warnock and progress on alternative routes to market in the US.